Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 137, Issue 4, Pages 595-605Publisher
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCPATBZ2JFN1QQC
Keywords
HER2 gene amplification; Breast cancer; In situ hybridization; Evidence-based reporting; Guidelines; Research
Categories
Ask authors/readers for more resources
International and national guidelines highlight the importance of accuracy, reproducibility, and quality control of in situ hybridization (ISH) methods for testing breast carcinomas. However, few guidelines cover the reporting of ISH cases with unusual signal patterns, including, eg, heterogeneity and loss of chromosome enumeration probe or gene signals. These cases are, in fact, relatively frequent, and there is a need for developing evidence- or consensus-based reporting guidelines to ensure consistency of treatment. Following an audit of cases from a single center (including > 1,700 cases) we show that approximately 10% of ISH results reflect unusual signal patterns. We illustrate the most common of these patterns and provide reporting guidelines for diagnosticians and recommendations for future research. Our goal is to ensure that in the future such rogues are reported in a consistent manner that, ultimately, will be supported by molecular and biochemical evidence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available